These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22629787)

  • 1. [The cost effectiveness of adalimumab in Crohn's disease (review of foreign pharmacoeconomic studies)].
    Rudakova AV
    Eksp Klin Gastroenterol; 2011; (9):113-9. PubMed ID: 22629787
    [No Abstract]   [Full Text] [Related]  

  • 2. I'm a patient: show me the trial data.
    Lomas A
    BMJ; 2013 Apr; 346():f2336. PubMed ID: 23596128
    [No Abstract]   [Full Text] [Related]  

  • 3. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of tumor necrosis factor in Crohn's disease].
    Rudakova AV
    Eksp Klin Gastroenterol; 2012; (5):83-6. PubMed ID: 23402177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.
    Erim DO; Mahendraratnam N; Okafor PN; Wheeler SB
    J Crohns Colitis; 2015 Aug; 9(8):669-75. PubMed ID: 25987351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis.
    Binion DG; Louis E; Oldenburg B; Mulani P; Bensimon AG; Yang M; Chao J
    Can J Gastroenterol; 2011 Sep; 25(9):492-6. PubMed ID: 21912760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of adalimumab in a patient with Crohn's disease and extensive generalised psoriasis who achieved complete remission of both conditions].
    Piqueras M; Monfort D; Pol MA; Galter S; Modolell I; Ortiz J; Boadas J
    Gastroenterol Hepatol; 2013; 36(6):396-9. PubMed ID: 23587662
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for a co-existing clinical condition of Crohn's disease and acrodermatitis continua of Hallopeau.
    Caputo F; Parro S; Zoli G
    J Crohns Colitis; 2011 Dec; 5(6):649. PubMed ID: 22115391
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
    Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recommendations for patients with Crohn's disease starting treatment with adalimumab: a rapid guide].
    Cabriada JL; García Sánchez V; Gomollón F; Hinojosa J; López San Román A; Mendoza JL; Mínguez M; Ricart E; Saro C
    Gastroenterol Hepatol; 2008 Dec; 31(10):693-7. PubMed ID: 19174086
    [No Abstract]   [Full Text] [Related]  

  • 13. Duodenal Crohn's disease successfully treated with adalimumab.
    Tursi A
    Endoscopy; 2011; 43 Suppl 2 UCTN():E22. PubMed ID: 21271523
    [No Abstract]   [Full Text] [Related]  

  • 14. Sjögren's syndrome associated with Crohn's disease successfully treated with adalimumab.
    Tursi A
    J Crohns Colitis; 2012 Mar; 6(2):263. PubMed ID: 22325185
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic strategy for patients with Crohn's disease using of adalimumab].
    Motoya S; Yamashita M; Tanaka H
    Nihon Shokakibyo Gakkai Zasshi; 2012 Mar; 109(3):370-7. PubMed ID: 22398901
    [No Abstract]   [Full Text] [Related]  

  • 17. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 18. [The use of adalimumab in severe fistulising Crohn's disease].
    Bang UC; Nielsen AM
    Ugeskr Laeger; 2008 Jun; 170(25):2256. PubMed ID: 18565318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonals against TNF are a major advance in the treatment of Crohn's disease.
    Fraser A
    N Z Med J; 2014 Jun; 127(1396):10-4. PubMed ID: 24997459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.